Isatuximab

10:42
Highlights from IMW 2019 Part I
Francesca Gay et al.
1:55
Katja Weisel: GMMG-CONCEPT
Katja Weisel
5:22
Updates on German clinical trials in multiple myeloma
Marc Raab
7:37
Prevention and management of adverse events in relapsed myeloma
Michel Delforge
3:30
Isatuximab: an important new option in R/R MM
Paul Richardson
1:24
Multiple myeloma treatment strategies: what does the future hold?
Enrique Ocio
2:24
Drug trial updates in multiple myeloma and SMM
Enrique Ocio
5:22
ICARIA study: Isatuximab and pom/dex for multiple myeloma
Paul Richardson
3:23
Upcoming updates in multiple myeloma
Thierry Facon
6:09
Induction in myeloma: a journey over time
Mohamad Mohty
3:11
Isatuximab plus VRd for newly diagnosed transplant-ineligible myeloma
Enrique Ocio
04:22
Mohamad Mohty’s myeloma highlights from ASH 2018
Mohamad Mohty
1:46
CD38 antibodies under investigation for myeloma: isatuximab, MOR202 & TAK-079
Niels van de Donk
2:41
Isatuximab: a ‘next-generation monoclonal antibody’
Paul Richardson
1:07
Promising results for isatuximab with carfilzomib in R/R MM
Ajai Chari
1:30
VCDI for multiple myeloma: an update
Enrique Ocio
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals